top of page
Till Erdmann

Co-Founder & Venture Partner

Till is a serial founder and angel investor with over 20 years life science experience in biopharma, diagnostics, digital health, and medtech. He founded Myelo Therapeutics (sold to Eckert & Ziegler AG), Treamid Therapeutics (secondary exit), and IDrug. Till has raised over €40m in venture capital and non-dilutive funding. An engineer and MBA by training, he previously worked in management consulting and in strategy, marketing, and commercial roles at Bayer Pharma and Thermo Fisher Scientific

Till Erdmann
bottom of page